Boardroom Alpha
Boardroom Alpha
MD · Additional Proxy Materials (DEFA14A) · Filed March 27, 2026

Pediatrix Medical Group Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
March 27, 2026
Ticker
MD
Accession
0001193125-26-127310
Boardroom Alpha · Filing insights

Pediatrix Medical Group's board urges shareholders to vote FOR Proposals 1-4 at the May 7, 2026 meeting.

About Pediatrix Medical Group Inc
Market cap
$1.8B
1Y TSR
+61.6%
3Y TSR
+17.3%
Board grade
B-
Sector
Healthcare
CEO
Mark S Ordan
Last annual meeting: May 7, 2026 · View full Pediatrix Medical Group Inc profile →
DEFA14A

 

 

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

 

 

 

SCHEDULE 14A INFORMATION

 

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934 (Amendment No.  )

 

 

 

Filed by the Registrant

 

Filed by a Party other than the Registrant

 

Check the appropriate box:

 

Preliminary Proxy Statement

 

 

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

 

Definitive Proxy Statement

 

 

Definitive Additional Materials

 

 

Soliciting Material under §240.14a-12

 

Pediatrix Medical Group, Inc.

(Name of Registrant as Specified In Its Charter)

 

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

 

Payment of Filing Fee (Check the appropriate box):

 

No Fee Required.

 

 

Fee paid previously with preliminary materials.

 

 

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

 

 


 

 

img122728874_0.jpg

 

LOGO P.O. BOX 8016, CARY, NC 27512-9903 Your vote matters! Pediatrix Medical Group, Inc. Annual Meeting of Shareholders Thursday, May 7, 2026 10:30 AM, Eastern Time Annual Meeting to be held live via the Internet - please visit www.proxydocs.com/MD for more details. You must register to attend the meeting online and/or participate at www.proxydocs.com/MD For a convenient way to view proxy materials, VOTE and obtain directions to attend the meeting go to www.proxydocs.com/MD To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet. If you want to receive a paper or e-mail copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before April 27, 2026. Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report or Form 10-K Important Notice Regarding the Availability of Proxy Materials for the Shareholders Meeting to be held on May 7, 2026 For Shareholders of record as of March 9, 2026 To order paper materials, use one of the following methods. Internet: www.investorelections.com/MD Call: 1-866-648-8affiliates. All Rights Reserved

 


 

 

img122728874_1.jpg

 

LOGO Pediatrix Medical Group, Inc. Annual Meeting of Shareholders THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR ON PROPOSALS 1, 2, 3 AND 4 PROPOSAL 1. Elect n2026 fiscal year; 3. Conduct an advisory vote regarding the compensation of our named executive officers for the 2025 fiscal year; and 4. Approve the Pediatrix Medical Group, Inc. Second Amended and Restated 2008 Incentive Compensation Plan 5. Consider and act upon such other business as may properly come before the annual meeting.

 


From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Pediatrix Medical Group Inc (MD)

Reference

Frequently asked questions

When did Pediatrix Medical Group Inc file this DEFA14A?
Pediatrix Medical Group Inc (MD) filed this Additional Proxy Materials (DEFA14A) with the SEC on March 27, 2026. The accession number assigned by EDGAR is 0001193125-26-127310.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Pediatrix Medical Group's board urges shareholders to vote FOR Proposals 1-4 at the May 7, 2026 meeting. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Pediatrix Medical Group Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Pediatrix Medical Group Inc has filed under CIK 893949, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer